从历史上看，挽救性化疗随后进行大剂量化疗和自体干细胞移植 (HDT/ASCT) 是治疗复发或难治性经典 HL 的主要方法。 HL 新型药物的出现，例如 brentuximab vedotin 和程序性死亡 1 (PD-1) 阻断剂，彻底改变了治疗策略，取得了优异的效果。本综述旨在对新的挽救疗法进行全面概述，并为即将推出的治疗方案提供见解。在 HDT/ASCT 之前将 brentuximab vedotin 和 PD-1 阻断纳入挽救疗法中，结果显着改善。值得注意的是，基于 PD-1 的挽救研究得出的移植后 2 年无进展生存率接近 90%，标志着霍奇金淋巴瘤 (HL) 治疗的显着进步。研究开始探索一线治疗失败后的非移植治疗方法，并可能确定适合这些策略的某些风险群体。HL 治疗的格局正在迅速发展，导致护理标准发生重大变化。现在，新型药物可以在病程早期施用，从而提高治愈率。治疗的重点正在转向以最小的毒性实现治愈，减少对各种药物的接触，并推进优化治疗顺序和低强度治疗患者选择的研究。版权所有 © 2024 Wolters Kluwer Health, Inc. 保留所有权利。

Historically, salvage chemotherapy followed by high-dose chemotherapy and autologous stem cell transplant (HDT/ASCT) was the mainstay approach for relapsed or refractory classic HL. The emergence of novel agents for HL, such as brentuximab vedotin and programmed death-1 (PD-1) blockade has revolutionized therapeutic strategies, yielding excellent results. This review aims to provide a comprehensive overview of new salvage therapies and offer insights into forthcoming therapeutic options.The incorporation of brentuximab vedotin and PD-1 blockade into salvage therapy before HDT/ASCT has led to markedly improved outcomes. Notably, PD-1 based salvage studies yield posttransplant 2-year progression-free survival rates approaching 90%, marking a significant advancement in the treatment of Hodgkin lymphoma (HL). Studies are beginning to explore nontransplant treatment approaches following front-line treatment failure and may identify certain risk groups eligible for these strategies.The landscape of HL treatment is rapidly evolving, leading to significant changes in the standard of care. Novel agents are now administered earlier in the disease course, resulting in higher cure rates. The focus of treatment is shifting towards achieving cure with minimal toxicity, reducing exposure to various agents, and advancing research in optimizing treatment sequencing and patient selection for less intensive therapies.Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.